Roche: launches in-vitro diagnostic to detect rare tumors
(CercleFinance.com) - Roche said it has launched the first automated in-vitro diagnostic immunohistochemistry assay to detect tropomyosin receptor kinase (TRK) proteins in cancer.
The launch will help laboratories identify fusion proteins through detection of the TRK C-terminal region, and perform analytic studies, including prevalence in solid tumors, the Swiss drugmaker said.
In some rare tumors, including infantile fibrosarcoma, and juvenile breast cancer, TRK fusion proteins are likely to be the defining genetic feature, it said.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The launch will help laboratories identify fusion proteins through detection of the TRK C-terminal region, and perform analytic studies, including prevalence in solid tumors, the Swiss drugmaker said.
In some rare tumors, including infantile fibrosarcoma, and juvenile breast cancer, TRK fusion proteins are likely to be the defining genetic feature, it said.
Copyright (c) 2018 CercleFinance.com. All rights reserved.